Niclosamide (BAY2353) sodium 为用于研究寄生虫感染的口服抗蠕虫化合物，同时是STAT3抑制剂，在HeLa细胞中IC50为0.25μM。此化合物显示抗癌生物活性，并可抑制Vero E6细胞DNA复制。

STAT3-IN-20（Compound 40）是一种选择性地靶向STAT3的SH2结构域，展现了在DU145和MDA-MB-231癌细胞中的抗增殖效果（IC50分别为2.97 μM和3.26 μM），并诱导细胞周期停滞与细胞凋亡。该抑制剂有效抑制了STAT3的磷酸化、核内易位及其下游基因的转录活性（IC50: 0.65 μM）。

Stafia-1-dipivaloyloxymethyl ester (compound 27) demonstrated a dose-dependent reduction in pSTAT5a expression (0-200 μM) while showing no discernible effect on pSTAT5b[1].

TP-5801 是口服具有活力的非受体酪氨酸激酶 (TNK1) 抑制剂，IC50 值为 1.40 nM，具有抗肿瘤作用。

Capillarisin is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells, it inhibits cancer cell growth of osteosarcoma cells by inducing apoptosis accompanied with

Manassantin B is a potent inhibitor of NF-κB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-κB. It also possesses anti-EBV lytic replication activity. Manassantin B inhibits interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells, it has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury. Manassantin B exerts antifibrotic activity in HSC-T6 cells, in part, via inhibition of cell proliferation and decrease of collagen production.